Monoclonal antibodies labeled with near-infrared (NIR) fluorophores have potential use in disease detection, intraoperative imaging, and pharmacokinetic characterization of therapeutic antibodies in both the preclinical and clinical setting. Recent work has shown conjugation of NIR fluorophores to antibodies can potentially alter antibody disposition at a sufficiently high degree of labeling (D...

The aim of the study was to assess the effects of bevacizumab in augmenting trabeculectomy for glaucoma. We searched the databases of Cochrane Library, PubMed, Embase, CNKI, and VIP. All the databases were retrieved from the time databases established to September, 2015. The keywords we used were as follows: "bevacizumab," "anti-VEGF," "avastin," "trabeculectomy," "glaucoma," and so on. We used...

CASE REPORT We present a 71-year-old patient with an Artisan(®) implant and macular oedema associated with unsatisfactory response to repeated intravitreal corticosteroids. An intravitreal Trigon(®) and Avastin(®) combined injection was given, and acute glaucoma developed. Anterior chamber washout was performed to resolve the rise in intraocular pressure. In spite of an excellent macular respon...

BACKGROUND Colorectal cancer (CRC) that has metastasized before being discovered, or reoccurs following surgery, remains a major treatment challenge. Trials have established the usefulness of antiangiogenic agents and new regimens in prolonging survival in patients with advanced disease. In the United States, the antiangiogenic agents approved for treating metastatic CRC often are combined with...

We report the use of bevacizumab (Avastin) as an additional strategy in angle closure glaucoma based on the case of 47 years old male qualified to cataract removal as anti-glaucoma procedure, in whom we observed iris and lens neovascularization. As a first step we administered 1.25 mg of bevacizumab into the anterior chamber. Iris as well as lens neovasularization completely disappeared after 4...

AV The angiogenesis inhibitor bevacizumab (Avastin, Genentech), which inhibits vascular endothelial growth factor A, has several benefits in metastatic colorectal cancer. It appears to confer a survival advantage, and depending on the study cited it also may add somewhat to response rate—although that depends on the agent it is paired with. Also, bevacizumab is generally well tolerated. The mai...

CONCLUSION Using data from PRICENTRICTM, we collected net and list ex-factory prices for Avastin, Caprelsa and Vidaza across EU-28. Countries that do not use formal IRP as a price setting mechanism were excluded from the analysis, countries that consider price reviews were included. In the case of Germany, the negotiated AMNOG price minus mandatory rebates was used, for Italy the AIFA price and...

To report the efficacy of combination therapy (bevacizumab and photocoagulation) in a case of Eales Disease this study has been performed. Bevacizumab (Avastin, 1.25 mg/0.05 ml) was injected intravitreously for the treatment of iris and retinal neovascularization in a 56-year old Hispanic female with photocoagulation treatment to control the recurrence of vitreous haemorrhage. Our results revea...

800x600 to report the efficacy of combination therapy (bevacizumab and photocoagulation) in a case of eales disease this study has been performed. bevacizumab (avastin, 1.25 mg/0.05 ml) was injected intravitreously for the treatment of iris and retinal neovascularization in a 56-year old hispanic female with photocoagulation treatment to control the recurrence of vitreous haemorrhage. our resul...

Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), and it has shown promise as a clinical agent against metastatic colorectal cancer, and particularly in combination with chemotherapy. Bowel perforation is a known risk that's associated with bevacizumab use, but the etiology is unknown. Here we report on two cases of metastatic colorectal cancer in whic...